Oğuzhan Birdal1, Mehmet Saygı2, Pınar Demir Gündoğmuş3, Emrah Aksakal4, Flora Özkalaycı2

1Atatürk University Faculty of Medicine, Department of Cardiology, Erzurum, Türkiye
2Hisar Intercontinental Hospital, Clinic of Cardiology, İstanbul, Türkiye
3Kırıkkale Yüksek İhtisas Hospital, Clinic of Cardiology, Kırıkkale, Türkiye
4Erzurum City Hospital, Clinic of Cardiology, Erzurum, Türkiye

Keywords: Angiotensin receptor neprilysin inhibitor; bayesian; ejection fraction

Abstract

Objectives: Heart failure is an important leading cause of mortality and morbidity despite the optimal medical treatment and device therapy. Sacubitril/valsartan, a first-generation drug, was approved to use heart failure treatment recently. There are limited studies on relationship between sacubitril/valsartan and left ventricular contraction. In our study, we aimed to evaluate the changes in left ventricular ejection fraction (LVEF) after sacubitril/valsartan treatment.

Patients and Methods: Fifty two patients with heart failure and reduced ejection fraction (HFrEF) were enrolled in this study. The baseline demographic, clinical and echocardiographic characteristics of 52 patients were compared using Bayesian method.

Results: Fifty two patients with heart failure and reduced ejection fraction (HFrEF) were included in final analysis (66.2 ± 9.3 years, 69.2% male). Sacubitril/valsartan initial dose was low in 44.2% of patients, intermediate in 55.8%. In low initial dose population; the increase in absolute LVEF was 3.87 (95% HDI 1.53-6.20) and in intermediate initial dose population; the increase in absolute LVEF was 5.89 (95% HDI 4.18-7.61). In female population; increase in absolute LVEF was 5.56 (95% HDI 3.49-7.63) and in male population 4.75 (95% HDI 2.91-6.58) respectively.

Conclusion: In this study, we demonstrated that sacubitril/valsartan is associated with increased LVEF regardless of baseline clinical characteristics.